UniProt ID | SL9A6_HUMAN | |
---|---|---|
UniProt AC | Q92581 | |
Protein Name | Sodium/hydrogen exchanger 6 | |
Gene Name | SLC9A6 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 669 | |
Subcellular Localization |
Endosome membrane Multi-pass membrane protein . Is present in the recycling compartments including early and recycling endosomes, and only appears transiently on the plasma membrane. |
|
Protein Description | Electroneutral exchange of protons for Na(+) and K(+) across the early and recycling endosome membranes. Contributes to calcium homeostasis.. | |
Protein Sequence | MARRGWRRAPLRRGVGSSPRARRLMRPLWLLLAVGVFDWAGASDGGGGEARAMDEEIVSEKQAEESHRQDSANLLIFILLLTLTILTIWLFKHRRARFLHETGLAMIYGLLVGLVLRYGIHVPSDVNNVTLSCEVQSSPTTLLVTFDPEVFFNILLPPIIFYAGYSLKRRHFFRNLGSILAYAFLGTAISCFVIGSIMYGCVTLMKVTGQLAGDFYFTDCLLFGAIVSATDPVTVLAIFHELQVDVELYALLFGESVLNDAVAIVLSSSIVAYQPAGDNSHTFDVTAMFKSIGIFLGIFSGSFAMGAATGVVTALVTKFTKLREFQLLETGLFFLMSWSTFLLAEAWGFTGVVAVLFCGITQAHYTYNNLSTESQHRTKQLFELLNFLAENFIFSYMGLTLFTFQNHVFNPTFVVGAFVAIFLGRAANIYPLSLLLNLGRRSKIGSNFQHMMMFAGLRGAMAFALAIRDTATYARQMMFSTTLLIVFFTVWVFGGGTTAMLSCLHIRVGVDSDQEHLGVPENERRTTKAESAWLFRMWYNFDHNYLKPLLTHSGPPLTTTLPACCGPIARCLTSPQAYENQEQLKDDDSDLILNDGDISLTYGDSTVNTEPATSSAPRRFMGNSSEDALDRELAFGDHELVIRGTRLVLPMDDSEPPLNLLDNTRHGPA | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
17 | Phosphorylation | PLRRGVGSSPRARRL CCCCCCCCCHHHHHH | 34.46 | - | |
88 (in isoform 3) | Phosphorylation | - | 2.42 | - | |
95 (in isoform 3) | Phosphorylation | - | 29.81 | - | |
128 | N-linked_Glycosylation | HVPSDVNNVTLSCEV CCCCCCCCEEEEEEE | 28.18 | 19159218 | |
140 (in isoform 2) | Phosphorylation | - | 31.83 | - | |
147 (in isoform 2) | Phosphorylation | - | 29.14 | - | |
166 | Phosphorylation | IIFYAGYSLKRRHFF HHHHCCCCHHHHHHH | 26.88 | 24719451 | |
443 | Ubiquitination | LNLGRRSKIGSNFQH HHCCCCCCCCCHHHH | 49.64 | 17370265 | |
446 | Phosphorylation | GRRSKIGSNFQHMMM CCCCCCCCHHHHHHH | 37.63 | 30631047 | |
480 | Phosphorylation | YARQMMFSTTLLIVF HHHHHHHHHHHHHHH | 11.55 | 24043423 | |
481 | Phosphorylation | ARQMMFSTTLLIVFF HHHHHHHHHHHHHHH | 15.36 | 24043423 | |
482 | Phosphorylation | RQMMFSTTLLIVFFT HHHHHHHHHHHHHHH | 20.54 | 24043423 | |
489 | Phosphorylation | TLLIVFFTVWVFGGG HHHHHHHHHHHHCCH | 11.29 | 24043423 | |
497 | Phosphorylation | VWVFGGGTTAMLSCL HHHHCCHHHHHHHHH | 18.04 | 24043423 | |
498 | Phosphorylation | WVFGGGTTAMLSCLH HHHCCHHHHHHHHHE | 17.22 | 24043423 | |
502 | Phosphorylation | GGTTAMLSCLHIRVG CHHHHHHHHHEEEEC | 11.10 | 24043423 | |
528 | Ubiquitination | ENERRTTKAESAWLF CCHHCCCHHHHHHHH | 49.93 | - | |
560 (in isoform 2) | Ubiquitination | - | 26.05 | - | |
573 | Phosphorylation | GPIARCLTSPQAYEN HHHHHHCCCHHHHCC | 41.82 | 25159151 | |
574 | Phosphorylation | PIARCLTSPQAYENQ HHHHHCCCHHHHCCH | 11.32 | 21815630 | |
589 | Phosphorylation | EQLKDDDSDLILNDG HHHCCCCCCCEECCC | 41.11 | 25849741 | |
599 | Phosphorylation | ILNDGDISLTYGDST EECCCCEEEEECCCC | 21.28 | 25159151 | |
601 | Phosphorylation | NDGDISLTYGDSTVN CCCCEEEEECCCCCC | 20.76 | 20639409 | |
602 | Phosphorylation | DGDISLTYGDSTVNT CCCEEEEECCCCCCC | 24.99 | 20639409 | |
605 | Phosphorylation | ISLTYGDSTVNTEPA EEEEECCCCCCCCCC | 29.86 | 20639409 | |
606 | Phosphorylation | SLTYGDSTVNTEPAT EEEECCCCCCCCCCC | 23.63 | 20639409 | |
609 | Phosphorylation | YGDSTVNTEPATSSA ECCCCCCCCCCCCCC | 38.72 | 20639409 | |
613 | Phosphorylation | TVNTEPATSSAPRRF CCCCCCCCCCCCCHH | 33.65 | 20639409 | |
614 | Phosphorylation | VNTEPATSSAPRRFM CCCCCCCCCCCCHHC | 26.98 | 20639409 | |
615 | Phosphorylation | NTEPATSSAPRRFMG CCCCCCCCCCCHHCC | 37.63 | 20639409 | |
624 | Phosphorylation | PRRFMGNSSEDALDR CCHHCCCCCHHHHHH | 29.40 | 26657352 | |
625 | Phosphorylation | RRFMGNSSEDALDRE CHHCCCCCHHHHHHH | 43.42 | 23911959 | |
654 | Phosphorylation | LVLPMDDSEPPLNLL EEEECCCCCCCCCCC | 47.97 | 28450419 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of SL9A6_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of SL9A6_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of SL9A6_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
SL9A7_HUMAN | SLC9A7 | physical | 28514442 | |
FUT8_HUMAN | FUT8 | physical | 28514442 | |
BROMI_HUMAN | TBC1D32 | physical | 28514442 | |
CDK20_HUMAN | CDK20 | physical | 28514442 | |
RAC3_HUMAN | RAC3 | physical | 28514442 | |
DJC30_HUMAN | DNAJC30 | physical | 28514442 | |
COA1_HUMAN | COA1 | physical | 28514442 | |
PMGT2_HUMAN | POMGNT2 | physical | 28514442 | |
PLD6_HUMAN | PLD6 | physical | 28514442 | |
AL3B1_HUMAN | ALDH3B1 | physical | 28514442 | |
MA2A2_HUMAN | MAN2A2 | physical | 28514442 | |
FGFR2_HUMAN | FGFR2 | physical | 28514442 | |
FKRP_HUMAN | FKRP | physical | 28514442 | |
S19A2_HUMAN | SLC19A2 | physical | 28514442 | |
INGR1_HUMAN | IFNGR1 | physical | 28514442 | |
SERC1_HUMAN | SERINC1 | physical | 28514442 | |
TM164_HUMAN | TMEM164 | physical | 28514442 | |
TM87A_HUMAN | TMEM87A | physical | 28514442 | |
MP3B2_HUMAN | MAP1LC3B2 | physical | 28514442 | |
AL3A2_HUMAN | ALDH3A2 | physical | 28514442 | |
YIPF3_HUMAN | YIPF3 | physical | 28514442 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
H00577 | Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Part | |||||
OMIM Disease | ||||||
300243 | Mental retardation, X-linked, syndromic, Christianson type (MRXSCH) | |||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
N-linked Glycosylation | |
Reference | PubMed |
"Glycoproteomics analysis of human liver tissue by combination ofmultiple enzyme digestion and hydrazide chemistry."; Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; J. Proteome Res. 8:651-661(2009). Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-128, AND MASSSPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-625, AND MASSSPECTROMETRY. | |
Ubiquitylation | |
Reference | PubMed |
"Tryptic digestion of ubiquitin standards reveals an improved strategyfor identifying ubiquitinated proteins by mass spectrometry."; Denis N.J., Vasilescu J., Lambert J.-P., Smith J.C., Figeys D.; Proteomics 7:868-874(2007). Cited for: UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-443, AND MASSSPECTROMETRY. |